
Bringing innovative ADC and SMDC medicines to cancer patients around the world
Founded in 2018, CanWell Pharma is led by several highly accomplished veterans who have an average of 25 years of experience in drug discovery and development in both U.S. and China biopharmaceutical industries. CanWell is dedicated to developing its proprietary first-in-class and best-in-class oncology products to address difficult-to-treat advanced cancers. CanWell is developing a rich R&D pipelines under our technology platforms.
Our Mission
Our mission at CanWell is to develop innovative treatments that harness the power of the immune system to fight cancer. We are devoted to leveraging the latest advances to further explore and develop a variety of innovative therapies. With a focus on collaboration, innovation and patient-centered care, we strive to be at the forefront of cancer therapy and bring new hope to patients and their families.

Antibody Drug Conjugate

Small Molecule Drug Conjugate
Latest News
CanWell will Present Latest ADC Program Updates at 16th World ADC in San Diego, CA (Nov 3-6, 2025)
CanWell Pharma will present it…
CanWell will Present Clinical Updates on an IFN-α Biased TLR7 Agonist CAN1012 at ESMO 2025 – Annual Meeting (October 17-21, 2025)
CanWell Pharma will present la…
CanWell will attend ADC & Novel Conjugates Partnering & Investment Summit (September 9-10, 2025)
CanWell Pharma will update com…
CanWell Pharma will Present Research Developments at The Society for Immunotherapy of Cancer (SITC) Annual Meeting
CanWell Pharma will present th…